Enanta Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript

Jan 10, 2023 / 11:00PM GMT
Eric William Joseph - JPMorgan Chase & Co, Research Division - VP & Senior Analyst

Okay. All right. We can get started. Good afternoon. I'm Eric Joseph, senior biotech analyst with JPMorgan, and our next presenting company is Enanta Pharmaceuticals. Presenting on behalf of the company is CEO, Jay Luly. And I just want to -- one program you note there's going to be a Q&A after the presentation. (Operator Instructions) So with that, Jay. Thank you.

Jay R. Luly - Enanta Pharmaceuticals, Inc. - President, CEO & Director

Thanks, Eric, and thank you very much for the opportunity to present again this year. Before I begin, I want to remind you, I'll be making some forward-looking statements. And for a summary, the risk associated with these statements, please see our filings on sec.gov and on our website. For those of you who are less familiar with Enanta, we are a virology-focused company, working on a number of different important viruses. A lot of them are in the respiratory category, respiratory viruses like RSV and COVID. We are also working on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot